Bioceres Crop Solutions Corp. (BIOX)
Bioceres Crop Solutions Corp. (BIOX) Q3 2026 Earnings Call Transcript
Bioceres Crop Solutions Corp. (BIOX) Q3 2026 Earnings Call Transcript
Bioceres Crop (BIOX) Reports Q3 Loss, Misses Revenue Estimates
Bioceres Crop (BIOX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.02 per share a year ago.
Bioceres Crop Solutions Corp. (BIOX) Shareholder/Analyst Call Prepared Remarks Transcript
Bioceres Crop Solutions Corp. (BIOX) Shareholder/Analyst Call Prepared Remarks Transcript
Bioceres Lenders Claim Default, And Dilution Risks Are Higher Than Ever
Bioceres reported 1Q26 results with continued revenue declines but improved gross margins and significant OpEx reductions, boosting profitability. BIOX faces severe financial risks, including default claims and lawsuits to accelerate over $100 million in debt, which it cannot cover with current cash. Equity holders face high dilution risk from convertible notes and potential asset sales, as the company cannot be evaluated as a going concern.
Bioceres Crop Solutions Corp. (BIOX) Q1 2026 Earnings Call Transcript
Bioceres Crop Solutions Corp. ( BIOX ) Q1 2026 Earnings Call November 13, 2025 8:30 AM EST Company Participants Paula Savanti - Head of Investor Relations Federico Trucco - Executive Chairman & CEO Conference Call Participants Austin Moeller - Canaccord Genuity Corp., Research Division Presentation Operator Good morning all, and thank you for joining us on today's Bioceres Crop Solutions Fiscal First Quarter 2026 Financial and Operational Results. My name is Drew, and I'll be the operator on the call today.
Bioceres Crop (BIOX) Reports Q1 Loss, Lags Revenue Estimates
Bioceres Crop (BIOX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.09 per share a year ago.
Bioceres Q3 2025 Illustrates The Financial Challenges And A Distressed Argentinian Market
Bioceres faces mounting financial stress, with Argentina's weak agriculture sector and loss of Syngenta payments driving revenue and EBITDA declines. Cash flow is tightening rapidly; asset sales and one-off inventory benefits are masking underlying losses, while debt and interest costs loom large. Long-term product developments like HB4 and RINO offer potential, but have yet to deliver meaningful, scalable revenue or margin improvements.
Bioceres Crop Solutions Corp. (BIOX) Q3 2025 Earnings Call Transcript
Bioceres Crop Solutions Corp. (NASDAQ:BIOX ) Q3 2025 Results Conference Call May 21, 2025 8:30 AM ET Company Participants Paula Savanti - Head, Investor Relations Federico Trucco - Chief Executive Officer Enrique López Lecube - Chief Financial Officer Milen Marinov - Chief Commercial Officer Conference Call Participants Kristen Owen - Oppenheimer Ben Klieve - Lake Street Capital Markets Austin Moeller - Canaccord Steve Byrne - Bank of America Kemp Dolliver - Brookline Capital Markets Operator Hello, everyone, and thank you for joining us on today's Bioceres Crop Solutions Fiscal Third Quarter 2025 Financial and Operational Results. My name is Drew and I'll be the operator on today's call.
Bioceres Crop (BIOX) Reports Q3 Loss, Misses Revenue Estimates
Bioceres Crop (BIOX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to earnings of $0.14 per share a year ago.
Bioceres Is Approaching Distressed Prices, But I Remain On The Sidelines
Bioceres Crop Solutions Corp. reported a disappointing Q2 2025 with revenues down 24%, driven by Argentina's economic crisis, despite improved international sales. BIOX stock is down 62% year-over-year, and I maintain a Hold rating due to concerns about the company's ability to turn around. The shift to a licensing model for HB4 technology and R&D cuts may improve short-term finances but pose long-term risks.
Bioceres Crop Solutions Corp. (BIOX) Q2 2025 Earnings Call Transcript
Bioceres Crop Solutions Corp. (BIOX) Q2 2025 Earnings Call Transcript
Bioceres Is Getting Cheaper, Not Yet An Opportunity But More Interesting
Bioceres' 1Q25 results were challenging due to adverse weather in Argentina, affecting crop nutrition, protection, and seeds, but potential recovery is expected in 2Q25. BIOX has depreciated significantly, now trading at $6.7 per share, with a market cap of $400 million, making it a more interesting Hold. Despite some improvements, HB4 commercialization remains underwhelming, and financial risks persist, warranting caution before investing in potential developments.
